Loading...
AVCT logo

Avacta Group PlcAIM:AVCT Stock Report

Market Cap UK£332.5m
Share Price
UK£0.71
UK£0.81
12.6% undervalued intrinsic discount
1Y111.3%
7D-0.7%
1D
Portfolio Value
​
View

Avacta Group Plc

AIM:AVCT Stock Report

Market Cap: UK£332.5m

Avacta Group (AVCT) Stock Overview

Engages in the development of cancer therapies in the United Kingdom, South Korea, and internationally. More details

AVCT fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Risk Analysis

Earnings have declined by 11.3% per year over past 5 years

Makes less than USD$1m in revenue (£113K)

Shareholders have been diluted in the past year

Volatile share price over the past 3 months compared to the UK market

+ 1 more risk

AVCT Community Fair Values

Create Narrative

See what 10 others think this stock is worth. Follow their fair value or set your own to get alerts.

Analyst Price Targets

View all narratives

Avacta Group Plc Competitors

Price History & Performance

Summary of share price highs, lows and changes for Avacta Group
Historical stock prices
Current Share PriceUK£0.71
52 Week HighUK£0.92
52 Week LowUK£0.28
Beta-0.068
1 Month Change-20.22%
3 Month Change0%
1 Year Change111.31%
3 Year Change-28.28%
5 Year Change-66.79%
Change since IPO-82.03%

Recent News & Updates

Recent updates

Analysis Article • Feb 19

Why Investors Shouldn't Be Surprised By Avacta Group Plc's (LON:AVCT) 26% Share Price Plunge

Avacta Group Plc ( LON:AVCT ) shareholders won't be pleased to see that the share price has had a very rough month...
Analysis Article • Nov 19

Avacta Group Plc's (LON:AVCT) 25% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Unfortunately for some shareholders, the Avacta Group Plc ( LON:AVCT ) share price has dived 25% in the last thirty...
Analysis Article • Oct 29

Is Avacta Group (LON:AVCT) Using Debt Sensibly?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analysis Article • Sep 05

Avacta Group Plc's (LON:AVCT) 29% Share Price Surge Not Quite Adding Up

Despite an already strong run, Avacta Group Plc ( LON:AVCT ) shares have been powering on, with a gain of 29% in the...
Analysis Article • Jun 21

Improved Revenues Required Before Avacta Group Plc (LON:AVCT) Shares Find Their Feet

Avacta Group Plc's ( LON:AVCT ) price-to-sales (or "P/S") ratio of 7x might make it look like a strong buy right now...
Analysis Article • Feb 23

Investors Give Avacta Group Plc (LON:AVCT) Shares A 26% Hiding

To the annoyance of some shareholders, Avacta Group Plc ( LON:AVCT ) shares are down a considerable 26% in the last...
Analysis Article • Aug 05

Getting In Cheap On Avacta Group Plc (LON:AVCT) Is Unlikely

Avacta Group Plc's ( LON:AVCT ) price-to-sales (or "P/S") ratio of 30.5x might make it look like a strong sell right...
Analysis Article • Jun 22

Would Avacta Group (LON:AVCT) Be Better Off With Less Debt?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Shareholder Returns

AVCTGB BiotechsGB Market
7D-0.7%-2.8%1.0%
1Y111.3%17.7%18.0%

Return vs Industry: AVCT exceeded the UK Biotechs industry which returned 14% over the past year.

Return vs Market: AVCT exceeded the UK Market which returned 15.5% over the past year.

Price Volatility

Is AVCT's price volatile compared to industry and market?
AVCT volatility
AVCT Average Weekly Movement8.4%
Biotechs Industry Average Movement8.4%
Market Average Movement5.6%
10% most volatile stocks in GB Market11.7%
10% least volatile stocks in GB Market3.1%

Stable Share Price: AVCT's share price has been volatile over the past 3 months compared to the UK market.

Volatility Over Time: AVCT's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of UK stocks.

About the Company

FoundedEmployeesCEOWebsite
2003151Chris Coughlinavacta.com

Avacta Group Plc, together with its subsidiaries, engages in the development of cancer therapies in the United Kingdom, South Korea, and internationally. Its lead product candidate is AVA6000, a peptide drug conjugate form of doxorubicin, which is an approved cancer drug with known severe toxicities. The company is developing AVA6103, a peptide drug conjugate technology designed to deliver exatecan, a potent topoisomerase I inhibitor directly to tumors while limiting the exposure of the released exatecan in normal tissues; and AVA7100 that drives localization to fibroblast activation protein expressing tumors.

Avacta Group Plc Fundamentals Summary

How do Avacta Group's earnings and revenue compare to its market cap?
AVCT fundamental statistics
Market capUK£332.51m
Earnings (TTM)-UK£37.06m
Revenue (TTM)UK£113.00k
2,943x
P/S Ratio
-9.0x
P/E Ratio

Is AVCT overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
AVCT income statement (TTM)
RevenueUK£113.00k
Cost of RevenueUK£0
Gross ProfitUK£113.00k
Other ExpensesUK£37.17m
Earnings-UK£37.06m

Last Reported Earnings

Dec 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-0.079
Gross Margin100.00%
Net Profit Margin-32,795.58%
Debt/Equity Ratio652.3%

How did AVCT perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/12 07:19
End of Day Share Price 2026/06/12 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Avacta Group Plc is covered by 6 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Lorenza CastellonEquity Development Limited
Julie SimmondsPanmure Liberum
Miles DixonPeel Hunt LLP